Sight Sciences Inc (SGHT) Q4 2025 Earnings Call Transcript

Why It Matters

The disciplined cost cuts and reimbursement wins position Sight Sciences to accelerate revenue growth while moving toward profitability, reshaping the interventional eye‑care market.

Key Takeaways

• Q4 revenue $20.4M, up 7% YoY
• Glaucoma revenue $19.7M, 5% growth, flat sequentially
• Dry eye revenue $0.7M, more than double prior year
• Operating expenses cut 25% after workforce reduction
• 2026 revenue guidance $82‑$88M, targeting double‑digit growth

Pulse Analysis

Sight Sciences’ fourth‑quarter results illustrate how strategic cost discipline can unlock profitability in niche medical device markets. By slashing operating expenses 25% through a targeted reduction in force, the company reduced its net loss by more than half while preserving a robust cash balance of $92 million. This financial tightening, combined with strong gross margins—87% overall and 88% in the glaucoma segment—creates a solid foundation for scaling its interventional product lines without relying on additional equity financing.

The reimbursement breakthrough for TearCare, secured through CPT code 0563T pricing by Novitas and First Coast MACs, marks a pivotal shift for the dry‑eye segment. Early traction—$700,000 in Q4 revenue from roughly 700 SmartLid units across 80 accounts—demonstrates the market’s appetite once procedural billing becomes viable. As the company expands its commercial team and targets high‑volume prescribers, the dry‑eye pipeline could grow from $1.6 million in 2025 to $5‑$7 million in 2026, unlocking a sizable addressable market of millions of MGD patients.

Looking ahead, Sight Sciences’ 2026 guidance of $82‑$88 million reflects confidence in both its glaucoma and dry‑eye franchises. The stabilization of LCD policies and continued pricing strength of the OMNI Edge device support incremental growth in the interventional glaucoma space, while the under‑penetrated standalone market offers additional upside. Together, these dynamics position the company to achieve sustainable double‑digit revenue expansion and move toward cash‑flow breakeven, signaling a compelling investment narrative for stakeholders in the evolving interventional eye‑care sector.